ELRiSE MDS
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 300 patients (estimated)
- Tags
- Activin Receptor IIA Inhibitor, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2232
- NCT Identifier
- NCT07422480
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.